Tigecycline induced acute pancreatitis: Suspicion is the first step in diagnosis

Year 2021, Volume: 3 Issue: 3 , 262 - 263 , 14.07.2021

Alpaslan Tanoğlu , Eylem Çağıltay

https://doi.org/10.38053/acmj.955678

Cited By: 1

https://izlik.org/JA86KR83CZ

Abstract

Acute pancreatitis is an inflammatory event of the pancreas which may affect seriously all other tissues and organ systems. Generally, acute pancreatitis is induced by alcoholism or gallstones. However pathogenetic mechanisms of drug induced pancreatitis are not clearly understood. A minocycline derivative, tigecycline is a glycylcycline class of antibiotic which is structurally similar to the tetracyclines. It has perfect tissue and organ distribution and favorable microbial coverage, including many kind of Gram-positive and Gram-negative bacteria and also anaerob agents. Tigecycline’s side-effect profile is similar to the tetracyclines. Pancreatitis is a well-known adverse effect of tetracyclines. However, tigecycline-induced pancreatitis is an uncommon side-effect. We report here a rare case of tigecycline-induced pancreatitis during the treatment of a diabetic food infection.

Keywords

Tigecycline , acute pancreatitis , advers effect

References

• Tanoglu A, Yazgan Y, Kaplan M, et al. Trimetazidine significantly reduces cerulein-induced pancreatic apoptosis. Clin Res Hepatol Gastroenterol 2015; 39: 145-50.
• Hançerli Y, Kaplan M, Tanoğlu A, et al. Efficacy of tocilizumab treatment in cerulein-induced experimental acute pancreatitis model in rats. Turk J Gastroenterol 2017; 28: 485-91.
• Kaplan M, Yazgan Y, Tanoglu A, et al. Effectiveness of interleukin-1 receptor antagonist (Anakinra) on cerulein-induced experimental acute pancreatitis in rats. Scand J Gastroenterol 2014; 49: 1124-30.
• Tanoglu A, Cagiltay E, Beyazit Y. Spiramycin-associated Acute Pancreatitis: Cause or Coincidence? Med Sci 2015; 4: 2352-5.
• Giamarellou H, Poulakou Pharmacokinetic and pharmacodynamic evaluation of tigecycline. Expert Opin Drug Metab Toxicol 2011; 7: 1459-70.
• Barbour A, Schmidt S, Ma B, Schiefelbein L, et al. Clinical pharmacokinetics and pharmacodynamics of tigecycline. Clin Pharmacokinet 2009; 48: 575-84.
• Brink AJ, Bizos D, Boffard KD, et al. Guideline summary: appropriate use of tigecycline. S Afr J Surg 2012; 50: 20-1.
• Lipshitz J, Kruh J, Cheung P, Cassagnol M. Tigecycline-induced pancreatitis. J Clin Gastroenterol 2009; 43: 93.
• Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.